FDA’s Win-Win: More Comprehensive IND Safety Reports With Minimal Effort Due To Harmonization
Executive Summary
New proposed rule calls for replacing US FDA’s current annual reporting requirements for INDs with a safety update report that is consistent the format and content of the development safety update report (DSUR) supported by the International Council of Harmonisiation.
You may also be interested in...
US adopts ICH DSUR format for annual clinical trial safety reports
The US Food and Drug Administration has adopted a guideline by the International Conference on Harmonisation that describes the format, content and timing of a development safety update report (DSUR) for an investigational drug1,2.
US FDA’s Anti-Misinformation Campaigns Look Safer After Supreme Court Oral Arguments
FDA’s efforts to tackle misinformation may face fewer legal obstacles moving forward, following oral arguments at the Supreme Court on a case that could have broad ramifications for how the government communicates public health information.
‘The Run Is Worth The Slide:’ FDA Advisors Urge Expansion Of J&J’s CAR-T Carvykti Despite Initial Upfront Treatment Risks
Oncologic Drugs Advisory Committee also favors earlier use of Bristol-Myers Squibb’s Abecma in multiple myeloma, although some members raise concerns about lack of plateau in progression-free survival benefit and equivocable overall survival data.